- Home
- CINT vs RCUS Comparison
CINT vs RCUS Comparison
Compare CINT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- RCUS
- Stock Information
- Founded
- CINT 1995
- RCUS 2015
- Country
- CINT Brazil
- RCUS United States
- Employees
- CINT N/A
- RCUS N/A
- Industry
- CINT EDP Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- RCUS Health Care
- Exchange
- CINT Nasdaq
- RCUS Nasdaq
- Market Cap
- CINT 833.8M
- RCUS 727.1M
- IPO Year
- CINT 2021
- RCUS 2018
- Fundamental
- Price
- CINT $5.15
- RCUS $8.10
- Analyst Decision
- CINT Buy
- RCUS Strong Buy
- Analyst Count
- CINT 6
- RCUS 10
- Target Price
- CINT $7.72
- RCUS $27.63
- AVG Volume (30 Days)
- CINT 112.0K
- RCUS 1.2M
- Earning Date
- CINT 05-21-2025
- RCUS 05-06-2025
- Dividend Yield
- CINT N/A
- RCUS N/A
- EPS Growth
- CINT 14.74
- RCUS N/A
- EPS
- CINT 0.22
- RCUS N/A
- Revenue
- CINT $438,961,000.00
- RCUS $258,000,000.00
- Revenue This Year
- CINT $537.19
- RCUS N/A
- Revenue Next Year
- CINT $14.48
- RCUS $25.77
- P/E Ratio
- CINT $23.42
- RCUS N/A
- Revenue Growth
- CINT N/A
- RCUS 120.51
- 52 Week Low
- CINT $3.34
- RCUS $6.50
- 52 Week High
- CINT $8.04
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CINT 39.92
- RCUS 47.40
- Support Level
- CINT $4.78
- RCUS $7.65
- Resistance Level
- CINT $5.13
- RCUS $8.36
- Average True Range (ATR)
- CINT 0.31
- RCUS 0.61
- MACD
- CINT 0.04
- RCUS 0.17
- Stochastic Oscillator
- CINT 53.28
- RCUS 79.60
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.